Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 25, 2026, 2:47 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Combination Therapy - Radiation Clear all
Withdrawn Phase 1Phase 2 Interventional

QUILT-3.072: NANT Hepatocellular Carcinoma (HCC) Vaccine

NCT03563170
View directory record Official record
Conditions
Hepatocellular Carcinoma Non-resectable, Hepatocellular Carcinoma Recurrent
Interventions
ETBX-011, GI-4000, haNK for infusion, avelumab, Capecitabine, Cyclophosphamide, 5-Fluorouracil, Leucovorin, nab-Paclitaxel, Sorafenib, SBRT, Aldoxorubicin hydrochloride, ETBX-051, ETBX-061, GI-6207, GI-6301, Cetuximab, N-803
Biological · Drug · Procedure
Lead sponsor
ImmunityBio, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
El Segundo, California
Source: ClinicalTrials.gov public record
Updated Mar 17, 2021 · Synced Sep 25, 2026, 2:47 PM EDT
Completed Not applicable Interventional Results available

Two Regimens of Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed Localized Ewing Sarcoma Family of Tumors

NCT00618813
View directory record Official record
Conditions
Ewing Sarcoma of Bone, Localized Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
Interventions
radiation therapy, therapeutic conventional surgery, etoposide, ifosfamide, doxorubicin hydrochloride, cyclophosphamide, vincristine sulfate, topotecan hydrochloride, filgrastim
Other · Drug · Biological
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 30 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
1
States / cities
Monrovia, California
Source: ClinicalTrials.gov public record
Updated Sep 24, 2014 · Synced Sep 25, 2026, 2:47 PM EDT
Completed Phase 2 Interventional

Androgen Suppression Plus Radiation Therapy in Treating Patients With Prostate Cancer

NCT00006359
View directory record Official record
Conditions
Prostate Cancer
Interventions
LHRH agonist, antiandrogen, radiation therapy, Brachytherapy boost
Drug · Radiation
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years to 120 Years · Male only
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2012
U.S. locations
26
States / cities
Lewes, Delaware • Newark, Delaware • Wilmington, Delaware + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2016 · Synced Sep 25, 2026, 2:47 PM EDT
Completed Phase 1 Interventional

TLR4 Agonist GLA-SE and Radiation Therapy in Treating Patients With Soft Tissue Sarcoma That Is Metastatic or Cannot Be Removed by Surgery

NCT02180698
View directory record Official record
Conditions
Stage III Adult Soft Tissue Sarcoma, Stage IV Adult Soft Tissue Sarcoma
Interventions
Laboratory Biomarker Analysis, Radiation Therapy, TLR4 Agonist GLA-SE
Other · Radiation · Drug
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 5, 2019 · Synced Sep 25, 2026, 2:47 PM EDT
Completed Phase 2 Interventional Results available

TVB- 2640 in Combination With Bevacizumab in Patients With First Relapse of High Grade Astrocytoma

NCT03032484
View directory record Official record
Conditions
Astrocytoma
Interventions
Bevacizumab, TVB-2640
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 14, 2023 · Synced Sep 25, 2026, 2:47 PM EDT
Completed Phase 2 Interventional Results available

Study of Cetuximab With Radiation Followed by Consolidation Chemotherapy for NSCLC

NCT00492206
View directory record Official record
Conditions
Non Small Cell Lung Cancer (NSCLC)
Interventions
Cetuximab
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
31
States / cities
Miami, Florida • Atlanta, Georgia • Baltimore, Maryland + 17 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2017 · Synced Sep 25, 2026, 2:47 PM EDT
Recruiting Phase 1Phase 2 Interventional

Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer

NCT04172532
View directory record Official record
Conditions
Locally Advanced Pancreatic Adenocarcinoma, Stage III Pancreatic Cancer AJCC v8
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Hypofractionated Radiation Therapy, Magnetic Resonance Imaging, Peposertib, Placebo Administration
Procedure · Radiation · Drug + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
44
States / cities
Duarte, California • Irvine, California • Orange, California + 35 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Sep 25, 2026, 2:47 PM EDT
Terminated Phase 2 Interventional Results available

BrUOG 355: Nivolumab to Tailored Radiation Therapy With Concomitant Cisplatin in the Treatment of Patients With Cervical Cancer

NCT03527264
View directory record Official record
Conditions
Cervical Cancer
Interventions
Nivolumab induction, Cisplatin, Radiation, Nivolumab with chemoradiation, Nivolumab maintenance
Drug · Radiation
Lead sponsor
Brown University
Other
Eligibility
18 Years and older · Female only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
2
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Apr 3, 2025 · Synced Sep 25, 2026, 2:47 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Maintenance Chemotherapy With or Without Local Consolidative Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer

NCT03137771
View directory record Official record
Conditions
Recurrent Non-Small Cell Lung Carcinoma, Stage IV Non-Small Cell Lung Cancer
Interventions
3-Dimensional Conformal Radiation Therapy (3D-CRT), Docetaxel, Gemcitabine, Intensity-Modulated Radiation Therapy (IMRT), Pemetrexed Disodium, Stereotactic Body Radiation Therapy (SBRT), Erlotinib Hydrochloride, Pembrolizumab
Radiation · Drug
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older
Enrollment
218 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2028
U.S. locations
296
States / cities
Birmingham, Alabama • Gilbert, Arizona • Peoria, Arizona + 228 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2026 · Synced Sep 25, 2026, 2:47 PM EDT
Not yet recruiting Phase 2 Interventional

Efficacy of Mirdametinib Alone or Combination With Radiotherapy for Germline and Sporadic NF1-Altered High-Grade Glioma

NCT07521657
View directory record Official record
Conditions
Neurofibromatosis 1 (NF1)
Interventions
mirdametinib with radiation, mirdametinib
Combination Product · Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
12 Years to 89 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced Sep 25, 2026, 2:47 PM EDT
Completed Phase 2 Interventional Results available

Sorafenib Tosylate, Combination Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With High-Risk Stage IIB-IV Soft Tissue Sarcoma

NCT02050919
View directory record Official record
Conditions
Pleomorphic Rhabdomyosarcoma, Stage IIB Adult Soft Tissue Sarcoma AJCC v7, Stage III Adult Soft Tissue Sarcoma AJCC v7, Stage IV Adult Soft Tissue Sarcoma AJCC v7
Interventions
Epirubicin Hydrochloride, External Beam Radiation Therapy, Ifosfamide, Laboratory Biomarker Analysis, Sorafenib Tosylate, Therapeutic Conventional Surgery
Drug · Radiation · Other + 1 more
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Mar 20, 2022 · Synced Sep 25, 2026, 2:47 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Phase I/II Study of Intratumoral Injection of SD-101

NCT02254772
View directory record Official record
Conditions
Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Small Lymphocytic Lymphoma, Splenic Marginal Zone Lymphoma
Interventions
Ipilimumab, SD-101, Radiation therapy
Biological · Drug · Radiation
Lead sponsor
Robert Lowsky
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Nov 26, 2019 · Synced Sep 25, 2026, 2:47 PM EDT
Completed Phase 3 Interventional

Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Rhabdomyosarcoma

NCT00002995
View directory record Official record
Conditions
Sarcoma
Interventions
dactinomycin, filgrastim, sargramostim, cyclophosphamide, vincristine sulfate, radiation therapy
Biological · Drug · Radiation
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 49 Years
Enrollment
483 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2011
U.S. locations
205
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 151 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2014 · Synced Sep 25, 2026, 2:47 PM EDT
Completed Phase 1 Interventional

Flavopiridol Plus Radiation Therapy Followed By Gemcitabine Hydrochloride in Treating Patients With Locally Advanced, Unresectable Pancreatic Cancer

NCT00047307
View directory record Official record
Conditions
Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer, Stage II Pancreatic Cancer, Stage III Pancreatic Cancer, Stage IV Pancreatic Cancer
Interventions
alvocidib, gemcitabine hydrochloride, 3-dimensional conformal radiation therapy, laboratory biomarker analysis
Drug · Radiation · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 3, 2013 · Synced Sep 25, 2026, 2:47 PM EDT
Completed Phase 2 Interventional Results available

Individualized Adaptive De-escalated Radiotherapy for HPV-related Oropharynx Cancer

NCT03416153
View directory record Official record
Conditions
Oropharynx Cancer
Interventions
Carboplatin, Radiation Therapy, Paclitaxel
Drug · Radiation
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
2
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Sep 25, 2026, 2:47 PM EDT
Recruiting Phase 2 Interventional

EMERALD: Endocrine Therapy oMission With Radiation in ER+ Breast Cancer: Assessing Quality of Life and Disease Control: a Prospective Phase II Trial

NCT06897488
View directory record Official record
Conditions
Breast Cancer
Interventions
Adjuvant Radiotherapy
Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
60 Years and older · Female only
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Sep 25, 2026, 2:47 PM EDT
Completed Phase 1 Interventional

Chemotherapy Combined With Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer

NCT00059761
View directory record Official record
Conditions
Lung Cancer
Interventions
cisplatin, irinotecan hydrochloride, radiation therapy
Drug · Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2013
U.S. locations
49
States / cities
Birmingham, Alabama • Burbank, California • Hayward, California + 39 more
Source: ClinicalTrials.gov public record
Updated Nov 16, 2015 · Synced Sep 25, 2026, 2:47 PM EDT
Recruiting Phase 1 Interventional

STARLITE for Unresectable High-Grade Gliomas

NCT06428045
View directory record Official record
Conditions
High Grade Glioma
Interventions
Magnetic Resonance (MR)-guided Laser Interstitial Thermal Therapy (LITT), Abacavir, Lamivudine, Ritonavir, Temozolomide, Focal Radiotherapy
Procedure · Drug · Radiation
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Sep 25, 2026, 2:47 PM EDT
Completed Phase 1 Interventional

Gefitinib, Paclitaxel, and Radiation Therapy in Treating Patients With Advanced or Recurrent Squamous Cell Carcinoma of the Head and Neck

NCT00083057
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
gefitinib, paclitaxel, radiation therapy
Drug · Radiation
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
2
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 14, 2012 · Synced Sep 25, 2026, 2:47 PM EDT
Completed Phase 1 Interventional

AdV-tk Therapy With Surgery and Chemoradiation for Pancreas Cancer (PaTK01)

NCT00638612
View directory record Official record
Conditions
Pancreatic Adenocarcinoma, Pancreatic Cancer
Interventions
AdV-tk, Valacyclovir
Biological · Drug
Lead sponsor
Candel Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
3
States / cities
Duarte, California • La Jolla, California • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 24, 2023 · Synced Sep 25, 2026, 2:47 PM EDT
Terminated Phase 2 Interventional Results available

Ph II Concurrent Chemo t/Docetaxel/Carboplatin/Radio Therapy-consolidation t/Locally Adv Inoperable Non-Small Cell Lung Cancer (NSCLC)

NCT00664105
View directory record Official record
Conditions
Lung Cancer
Interventions
Carboplatin, Docetaxel, radiation therapy
Drug · Radiation
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
15
States / cities
Orlando, Florida • Baltimore, Maryland • Cleveland, Ohio + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 6, 2012 · Synced Sep 25, 2026, 2:47 PM EDT
Recruiting Not applicable Interventional

Treatment of Brain AVMs (TOBAS) Study

NCT02098252
View directory record Official record
Conditions
Unruptured Brain Arteriovenous Malformation, Ruptured Brain Arteriovenous Malformation, Arteriovenous Malformations, AVM, BAVM
Interventions
Neurosurgery, Radiation therapy, Embolization
Procedure · Radiation
Lead sponsor
Centre hospitalier de l'Université de Montréal (CHUM)
Other
Eligibility
5 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2036
U.S. locations
3
States / cities
Jacksonville, Florida • Boston, Massachusetts • Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Aug 14, 2024 · Synced Sep 25, 2026, 2:47 PM EDT
Completed Phase 1Phase 2 Interventional

Combined Modality Treatment for Patients With Stage IV Melanoma

NCT00313235
View directory record Official record
Conditions
Malignant Melanoma Stage IV
Interventions
DC Vaccine and Cyclophosphamide
Biological
Lead sponsor
Baylor Research Institute
Other
Eligibility
21 Years to 75 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 12, 2013 · Synced Sep 25, 2026, 2:47 PM EDT
Active, not recruiting Phase 1 Interventional

OKN-007 in Combination With Adjuvant Temozolomide Chemoradiotherapy for Newly Diagnosed Glioblastoma

NCT03587038
View directory record Official record
Conditions
Glioblastoma
Interventions
OKN 007, Temozolomide, Photon/Proton IMRT
Drug · Radiation
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years to 99 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Sep 25, 2026, 2:47 PM EDT